MetaCap

HCW Biologics (HCWB) vs Purple Biotech (PPBT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

HCW Biologics is the larger company by market cap ($2.4 million vs $1.9 million), about 1.3 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HCWB-51.98%PPBT+4.45%
+21%-18%-56%
Oct 7, 20261 yearNov 20, 2026
HCWB-53.18%PPBT+14.66%
+26%-15%-57%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HCWB versus PPBT key metrics
MetricHCWBPPBT
Share price$0.7491$1.53
Market cap$2.35M$1.86M
1-day change+1.90%-4.09%
EPS (TTM)$-9.09$-47.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$54.23K—
Revenue growth (YoY)-97.89%—
Net income (latest FY)$-7.96M$-26.39M
Gross margin20.00%—
Operating margin-24270.74%—
Net margin-14677.14%—
52-week high$23.94$8.90
52-week low$0.70$0.91
Distance from 52-week high-96.87%-82.87%
Analyst consensusbuynone
Avg. price target upside+6307.69%+1014.75%
Average volume379.38K1.26M
Shares outstanding3.14M1.22M
Employees3510
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About HCW Biologics

HCWB stock →

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees

About Purple Biotech

PPBT stock →

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

HCWB vs PPBT FAQ

Which is bigger, HCW Biologics or Purple Biotech?

HCW Biologics (HCWB) is larger, with a market capitalization of $2.35M compared with $1.86M for Purple Biotech (PPBT).

Are HCW Biologics and Purple Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons